Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: Current concepts at the bench

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 6, 2005, Pages 519-524

  El Abbadi, Mohga ^a   Giachelli, Cecilia M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Arteriosclerosis; Atherosclerosis; Chronic kidney disease; Dialysis; End stage renal disease; Uremia; Vascular calcification

Indexed keywords

CALCIUM; CALCIUM PHOSPHATE; CYTOKINE; FETUIN; OSTEOCALCIN; OSTEOPONTIN; PHOSPHATE; PYROPHOSPHATE;

ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CELL DEATH; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; DIALYSIS; GENETICS; HUMAN; HYDROLYSIS; MINERALIZATION; NONHUMAN; OSTEOPOROSIS; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; UREMIA;

EID: 27444436071     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000168335.29381.23     Document Type: Review

References (66)

1. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998; 11:239-245.
2. Eifinger F, Wahn F, Querfeld U, et al. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 2000; 15:1892-1894.
3. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15:218-223.
4. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18:1731-1740.
5. Moe SM, O'Neill KD, Reslerova M, et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004; 19:2387-2393.
6. Sangiorgi G, Rumberger JA, Severson A, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 1998; 31:126-133.
7. Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000; 101:850-855.
8. Burke AP, Taylor A, Farb A, et al. Coronary calcification: insights from sudden coronary death victims. Z Kardiol 2000; 89 (Suppl 2):49-53.
9. Ehara S, Kobayashi Y, Yoshiyama M, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 2004; 110:3424-3429. This study of 178 patients prior to intervention used intravascular ultrasound to compare morphology of calcification associated with acute or stable coronary syndromes. Numerous small, spotty calcifications in fibrofatty lesions characterized vulnerable plaques, whereas lesions in stable angina pectoris had fewer but larger calcium deposits. This study underscores the difficulty in determining the role of calcification in plaque stability based solely on finite element models.
10. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-942.
11. Haydar AA, Covic A, Colhoun H, et al. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004; 65:1790-1794.
12. Pannier B, Guerin AP, Marchais SJ, et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 2005; 45:592-596. In a cohort of 305 patients, increased stiffness of the aorta estimated by measuring pulse wave velocity was a strong predictor of cardiovascular mortality in ESRD patients.
13. Moe SM, Chen NX. Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatr Nephrol 2003; 18:969-975.
14. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44 (5 Suppl 3): 34-38. A large epidemiological study confirming the association of all cause and cardiovascular disease mortality with serum phosphorus, calcium, and Ca × P, and parathyroid hormone.
15. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16:520-528. In this retrospective cohort study, risk of all-cause mortality was independently associated with serum phosphate levels > 3.5 mg/dl in nondialysis CKD patients.
16. Kerr DN. Hypercalcemia and metastatic calcification. Cardiovasc Res 1997; 36:293-297.
17. Haffner D, Hocher B, Muller D, et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 2005; 23:1067-1075.
18. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-1483.
19. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100-105.
20. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15:1014-1021.
21. Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004; 62:104-115.
22. Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1489-1496. This study follows up earlier clinical trial results and shows that calcium-based phosphate binders are associated with progressive coronary artery and aortic calcification, and that among calcium-treated patients, higher calcification scores were associated with higher serum calcium, phosphorus and Ca × P.
23. Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol 2004; 13:63-70.
24. Luo GDP, McKee MD, Pinero GJ, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386:78-81.
25. Hur DJ, Raymond GV, Kahler SG, et al. A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A 2005; 135:36-40.
26. Zebboudj AF, Shin V, Bostrom K. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 2003; 90:756-765.
27. Price PA, Caputo JM, Williamson MK. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. J Bone Miner Res 2002; 17:1171-1179.
28. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165:625-630.
29. Jono S, Ikari Y, Vermeer C, et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004; 91:790-794.
30. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67:2295-2304.
31. Schurgers U, Teunissen KJ, Knapen MH, et al. Novel conformation-specific antibodies against matrix {gamma}-carboxyglutamic acid (Gla) protein: under-carboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25:1629-1633. This paper demonstrates for the first time that impaired carboxylation of MGP is associated with intimai and medial vascular calcification.
32. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 2005; 14:337-342.
33. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetum-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112:357-366.
34. Szweras M, Liu D, Partridge EA, et al. Alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002; 277:19991-19997.
35. Mathews ST, Singh GP, Ranalletta M, et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002; 51:2450-2458.
36. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827-833.
37. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67:2383-2392. This recent cohort study on 258 ESRD patients not only establishes an association between low serum fetuin-A levels and cardiovascular mortality in CKD, but also links increased inflammation with the decreased fetuin-A levels.
38. Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67:1070-1077.
39. Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20:1676-1685. This study on 238 peritoneal dialysis patients links increased vascular calcification with elevated C-reactive protein levels and low fetuin-A levels and confirms that fetuin-A is a significant predictor of all-cause mortality.
40. Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003; 34:379-381.
41. Harmey D, Hessle L, Nansawa S, et al. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164:1199-1209.
42. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/-mice. Arterioscler Thromb Vasc Biol 2005; 25:686-691.
43. Johnson K, Goding J, Van Etten D, et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003; 18:994-1004.
44. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16:2495-2500. This is the first study to link hemodialysis patients with reduced plasma pyrophosphate levels, underscoring the significance of pyrophosphate as a regulator of vascular calcification in CKD. The study also determines that a significant amount of pyrophosphate is further cleared during dialysis.
45. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000; 19:615-622.
46. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300 (Pt 3):723-728.
47. Wada T, McKee MD, Stietz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84:1-6.
48. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000; 275:20197-20203.
49. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; 196:1047-1055.
50. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; 161:2035-2046.
51. Ohri R, Tung E, Rajachar R, Giachelli CM. Mitigation of ectopic calcification in osteopontin-deficient mice by exogenous osteopontin. Calcif Tissue Int 2005; 76:307-315. A significant in-vivo study demonstrating the ability of exogenously applied osteopontin to rescue calcification of gluteraldehyde-fixed bovine pericardium inplants as well as to show that osteopontin's prevention of mineralization is dependent on its phosphorylation and a functional RGD motif.
52. Nitta K, Ishizuka T, Horita S, et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron 2001; 89:455-458.
53. Tintut Y, Alfonso Z, Saini T, et al. Multilineage potential of cells from the artery wall. Circulation 2003; 108:2505-2510.
54. Towler DA, Bidder M, Latifi T, et al. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273:30427-30434.
55. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87:E10-E17.
56. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89:1147-1154.
57. Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61:638-647.
58. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 1976; 35:156-162.
59. Giachelli CM. Ectopic calcification: new concepts in cellular regulation. Z Kardiol 2001 ; 90 (Suppl 3):31-37.
60. Proudfoot D, Skepper JN, Hegyi L, et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87:1055-1062.
61. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15:2857-2867.
62. Banks LM, Lees B, MacSweeney JE, Stevenson JC. Effect of degenerative spinal and aortic calcification on bone density measurements in postmenopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest 1994; 24:813-817.
63. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268.
64. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21:817-824.
65. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21:1610-1616.
66. Nitta K, Akiba T, Uchida K, et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1886-1889. A study on 102 hemodialysis patients that reports an unexpected positive correlation between serum steoprotegerin levels and the grade of aortic calcification, supporting the correlation between steoprotegerin and bone loss. The study also suggests a possible role of steoprotegerin in the pathogenesis of chronic inflammation in dialysis patients.